David D. Meek - 14 Jan 2022 Form 4 Insider Report for Mirati Therapeutics, Inc.

Role: Chief Executive Officer, Director
Signature: /s/ Vickie Reed, Attorney-inFact
Issuer symbol: N/A
Transactions as of: 14 Jan 2022
Net transactions value: $0
Form type: 4
Filing time: 18 Jan 2022, 17:20:06 UTC
Previous filing: 24 Sep 2021
Next filing: 19 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	MRTX	Common Stock	Award	$0	+34,057		$0.000000	34,057	14 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	MRTX	Employee Stock Option (Right to Buy)	Award	$0	+56,433		$0.000000	56,433	14 Jan 2022	Common Stock	56,433	$124.31	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Grant of Restricted Stock Units (RSUs). Shares will vest 25% annually on the anniversary of the grant date until fully vested.
F2	25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the date of grant, and 1/48th of the shares subject to the Option shall vest each month thereafter until fully vested.